Atossa Genetics Inc news

   Watch this stock
Showing stories 1 - 10 of about 77   

Articles published

ATOS 0.230 -0.010 (-4.17%)
price chart
Atossa Genetics' COO Scott Youmans Resigns (NASDAQ:ATOS)
Atossa Genetics (NASDAQ:ATOS), a health care company, disclosed in a regulatory filing on Tuesday that Scott Youmans is departing as the company's chief operating officer effective Feb. 12, 2016. Youmans said he will be pursuing other professional ...
Ambitious Atossa Genetics Going After Two Breast Cancer Blockbusters
Atossa Genetics (NASDAQ:ATOS) is a small biotech with two primary candidates. The first is a gel reformulation of ... Atossa has licensed a gel reformulation of AstraZeneca's (NYSE:AZN) Nolvadex, better known as generic tamoxifen. Tamoxifen is the most ...
Atossa Genetics Inc (ATOS) to Post FY2020 Earnings of ($0.19) Per Share, Zacks ...
Atossa Genetics logo Atossa Genetics Inc (NASDAQ:ATOS) - Zacks Investment Research issued their FY2020 EPS estimates for shares of Atossa Genetics in a research note issued to investors on Tuesday, according to Zacks Investment Research.
Atossa Genetics: Spotty Track Record And Short On Cash (ATOS)
The company had known that FDA was concerned about the changes the company made to the system when FDA inspected the facility in July 212.
FY2016 EPS Estimates for Atossa Genetics Inc (ATOS) Lifted by Zacks Investment ...
Atossa Genetics logo Atossa Genetics Inc (NASDAQ:ATOS) - Equities research analysts at Zacks Investment Research raised their FY2016 earnings estimates for shares of Atossa Genetics in a report issued on Tuesday, according to Zacks Investment ...
Atossa Genetics Inc (ATOS) Expected to Earn FY2020 Earnings of ($0.19) Per Share  Corvus Business Newswire
Atossa Genetics Inc Forecasted to Earn FY2020 Earnings of ($0.19) Per Share ...  IRA Market Report
Atossa Genetics (ATOS) Stock Declines Today on Heavy Trading Volume
"We rate ATOSSA GENETICS INC (ATOS) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the ...
Related articles »  
Atossa Genetics Incorporated (NASDAQ:ATOS) Sellers Increased By 38.29% Their ...
The short interest to Atossa Genetics Incorporated's float is 0.72%. The stock increased 4.00% or $0.01 on February 5, hitting $0.26.
Atossa Genetics Inc (ATOS) Files Form 4 Insider Buying : Steven C Quay Buys ...
Atossa Genetics Inc (ATOS): Steven C Quay , CEO of Atossa Genetics Inc purchased 50,000 shares on Jan 19, 2016. The Insider buying transaction was disclosed on Jan 21, 2016 to the Securities and Exchange Commission in a Form-4 filing.
The President & CEO of Atossa Genetics (NASDAQ: ATOS) is Buying Shares  Analyst Ratings
Atossa Genetics Inc. (ATOS) Adopts Poison Pill Provision
Atossa Genetics Inc. (Nasdaq: ATOS) announced that its Board of Directors has approved the adoption of a stockholder rights agreement.
Related articles »  
Atossa Genetics secures global license to Afimoxifene Gel (ATOS)
Atossa Genetics (ATOS +11.7%) inks a 15-year worldwide exclusive license agreement with Besins Healthcare Luxembourg SARL for its patented gel formulation of 4-Hydroxytamoxifen or Afimoxifene Gel for the potential treatment and prevention of ...
Atossa Genetics, Inc. (NASDAQ:ATOS) Has Huge Plans to Reverse the Downtrend  HotStocked
Atossa Genetics (ATOS) Acquires Afimoxifene Gel License from Besins  StreetInsider.com